drugset / Trial / NCT02863705

Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

NCT02863705

Phase 4 Completed 118 enrolled Allergan
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the long-term efficacy and safety of COMBIGAN® (brimonidine tartrate/timolol malate) in patients only using COMBIGAN® (brimonidine tartrate/timolol malate) and also in patients who require additional IOP lowering with LUMIGAN® (bimatoprost) 0.01%.

Timeline

Start
2016-07-05
Primary completion
2018-07-25
Completion
2018-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.01 % Other
Subject Brimonidine Small molecule Other
Subject Timolol Other / unclassified Other

Indications